Spirit Realty Capital

– SRC recommended that the trial escalate to the next dose level of 30mg capsule – – No dose-limiting toxicities (DLT's) or rash observed to date – MIAMI, April 10, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced that the external Safety Review Committee recommended that the Company's Phase 1 clinical trial of PAS-004 in advanced cancer should proceed to Cohort 6, 30mg capsule, without modification. This recommendation was based on the review of the safety data from three patients from Cohort 5 and the absence of any dose limiting toxicities (DLT's).» Mehr auf globenewswire.com

Toronto, Ontario--(Newsfile Corp. - March 11, 2025) - Stakeholder Gold Corp. (TSXV: SRC) (OTC Pink: SKHRF)  ("Stakeholder" or the "Company") is pleased to announce that the Company has submitted a Class 1 Notification for 2025 exploration on the Ballarat Gold-Copper Project; including maiden drilling on the Skye Gold Zone and the Loki Copper Zone. Ballarat Exploration Program 2025 The Company is planning to drill 2,500 meters over 8 - 10 drill holes targeting two previously identified and documented zones of mineralization, the Skye Gold Zone and the Loki Copper Zone.» Mehr auf newsfilecorp.com

Toronto, Ontario--(Newsfile Corp. - February 13, 2025) - Stakeholder Gold Corp. (TSXV: SRC) (OTC Pink: SKHRF) ("Stakeholder" or the "Company") is pleased to announce first sales from the Company's third quarry in Minas Gerais, Brazil. The quarry produces white quartzite blocks for cutting and polishing into slabs.» Mehr auf newsfilecorp.com